im all in at 12 cents, page-2

The pressure will be on - and I mean REALLY on to strike up some sort of collaboration on one of their products.

My guess would be that Metabolic would want to hang onto ACV1 and license development of AOD9604 for osteoporosis, but either way, they must seek a partner for one of these - and soon.

As noted below, management has access to data that might (or might not) be useful inmaking a case for a serious trial effort of AOD9604 for osteoporosis.